Physician profile
Michael T Guffey
NPI 1265431811
$949.07
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $142.94 | 2019-2020 | |
| Pfizer INC. | $124.72 | 2019-2020 | |
| Lilly USA, LLC | $108.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $84.98 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.16 | 2019-2020 | |
| Amgen INC. | $60.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.05 | 2019-2020 | |
| Amarin Pharma, INC. | $49.93 | 2019-2020 | |
| Novo Nordisk INC | $41.23 | 2019 | |
| Merck Sharp & Dohme LLC | $39.49 | 2019 | |
| Astellas Pharma US INC | $28.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.75 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.20 | 2019-2020 | |
| Allergan, INC. | $25.17 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.14 | 2019 | |
| Horizon Therapeutics Plc | $11.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.